JDRF announced a partnership with EOFlow, a South Korean medical device company, to develop a patch pump automated insulin delivery system. EOFlow currently has two diabetes pipeline products including a wearable insulin pump-only (EOPatch) and an artificial pancreas system (EOPancreas).
In early January AZ announced the availability of Bydureon BCise autoinjector in US pharmacies after receiving FDA approval in Oct 2017. FENIX has conducted GLP-1RA market, pricing, and co-pay card analyses.
Lilly disclosed major announcements about its diabetes connected care strategy, including intentions to develop an in-house automated insulin-delivery (AID) device as well as a wireless smart pen injection device. As a part of this endeavor, Lilly has engaged in collaborations with Deka R&D Corp., CGM-manufacturer Dexcom, and acquired Montreal-based algorithm startup Class AP. In light of these developments, Lilly has indicated plans to initiate trials by YE 2017 and has suggested it will take 2-3 years for these new devices to reach the market.
Tandem Diabetes Care hosted its Q3 ’17 earnings call and provided updates to its pump business including the closed-loop programs. Below are highlights from the call.
Tandem hosted their Q2 ’17 earnings call and issued a press release, providing financial updates as well as updates regarding t:slim LCM.
J&J presented its Q1 ’17 earnings results and provided a brief update to its diabetes business including drugs and devices. Of note, J&J is hosting its Pharmaceutical Business Review on May 17.